Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + CD19/CD22 CAR-T in Elderly Ph+ ALL
NCT05523661Phase 1Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD22 bispecific CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Shanghai General Hospital. Primary endpoint: Number of patients achieving molecular Complete Remission at 3 months. Status: unknown.
02
Drugs
CD22 bispecific CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05523661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523661.